Obesity - HealthQuill

A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the current guidelines for cholesterol and high blood pressure treatment remain the same, according to a Harvard Medical School study.

New cardiovascular risk calculator may impose a burden on 16 million US citizens

HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.

by HealthQuill
August 6, 2024
0 Comments

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.

Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

by HealthQuill
August 1, 2024
0 Comments

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering from heart problems or stroke.

Drugs Health Pharma

Novo Nordisk’s Wegovy gets UK regulator nod to treat heart risks

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.

by HealthQuill
July 24, 2024
0 Comments

Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.

Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients

Tirzepatide, an obesity drug of Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

by HealthQuill
June 22, 2024
0 Comments

Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.

Drugs Health Pharma

7-fold increase in use of GLP-1 weight loss drugs among teens, young adults

Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults

by HealthQuill
May 23, 2024
0 Comments

Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.

Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

by HealthQuill
May 2, 2024
0 Comments

Experiencing a way to eat out of a stressful situation —even in the absence of appetite — is a very common occurrence and it is an underrated reason for morbid obesity.

Drugs Health Opinion Pharma

Opinion: Overeating under stress can alter your neurochemistry

By Aparna S April 22, 2024: Stress is an underrated cause of obesity — the gateway for many lifestyle diseases in today’s sedentary.

by HealthQuill
April 22, 2024
0 Comments

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.

Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.